MDT

88.5

+2.03%↑

121.44

+5.27%↑

VEEV

159.3

+1.54%↑

HQY

80.55

+2.81%↑

TLRY

6.95

+7.42%↑

MDT

88.5

+2.03%↑

121.44

+5.27%↑

VEEV

159.3

+1.54%↑

HQY

80.55

+2.81%↑

TLRY

6.95

+7.42%↑

MDT

88.5

+2.03%↑

121.44

+5.27%↑

VEEV

159.3

+1.54%↑

HQY

80.55

+2.81%↑

TLRY

6.95

+7.42%↑

MDT

88.5

+2.03%↑

121.44

+5.27%↑

VEEV

159.3

+1.54%↑

HQY

80.55

+2.81%↑

TLRY

6.95

+7.42%↑

MDT

88.5

+2.03%↑

121.44

+5.27%↑

VEEV

159.3

+1.54%↑

HQY

80.55

+2.81%↑

TLRY

6.95

+7.42%↑

Home・Stock List・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Open

SectorHealthcare

21.47

Buy Sell

Overview

Share price change

24h

Current

Min

21.46

Max

21.47

Key metrics
By Trading Economics
Income	-1.6M -21M
Sales	14M 54M
Profit margin	-39.611
Employees	178
EBITDA	-3.8M -23M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	-2.84% downside

Dividends
By Dow Jones
Next Earnings	5 May 2026

Market Stats
By TradingEconomics
Market Cap	1B 2.2B
Previous open	21.47
Previous close	21.47

News Sentiment

By Acuity

50%

154 / 348 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

6.26 / 7.47 Support & Resistance

Day One Biopharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

13 Apr 2026, 23:25 UTC

Major News Events

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

13 Apr 2026, 22:45 UTC

Major News Events

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

13 Apr 2026, 18:03 UTC

Earnings

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

13 Apr 2026, 23:58 UTC

Earnings

Review & Preview: Earnings Time -- Barrons.com

13 Apr 2026, 23:49 UTC

Market Talk

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

13 Apr 2026, 23:33 UTC

Market Talk

Major News Events

Gold Edges Higher Amid Dollar Weakness -- Market Talk

13 Apr 2026, 23:20 UTC

Market Talk

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

13 Apr 2026, 23:01 UTC

Earnings

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

13 Apr 2026, 23:01 UTC

Earnings

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

13 Apr 2026, 23:01 UTC

Earnings

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

13 Apr 2026, 22:21 UTC

Acquisitions, Mergers, Takeovers

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

13 Apr 2026, 21:53 UTC

Earnings

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

13 Apr 2026, 21:53 UTC

Earnings

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

13 Apr 2026, 21:53 UTC

Earnings

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

13 Apr 2026, 21:53 UTC

Earnings

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

13 Apr 2026, 21:26 UTC

Major News Events

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

13 Apr 2026, 21:23 UTC

Earnings

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

13 Apr 2026, 21:16 UTC

Earnings

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

13 Apr 2026, 20:50 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

13 Apr 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

13 Apr 2026, 20:34 UTC

Earnings

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

13 Apr 2026, 20:34 UTC

Earnings

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

13 Apr 2026, 20:34 UTC

Earnings

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

13 Apr 2026, 19:59 UTC

Market Talk

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

13 Apr 2026, 19:50 UTC

Market Talk

Major News Events

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

13 Apr 2026, 19:27 UTC

Market Talk

Major News Events

Correction to Precious Metals Market Talk on April 9

13 Apr 2026, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

13 Apr 2026, 18:59 UTC

Market Talk

Major News Events

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

13 Apr 2026, 18:59 UTC

Market Talk

Major News Events

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

13 Apr 2026, 18:43 UTC

Market Talk

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Peer Comparison

Price change

Day One Biopharmaceuticals Inc Forecast

Price Target

By TipRanks

-2.84% downside

12 Months Forecast

Average 20.86 USD -2.84%

High 21.5 USD

Low 17 USD

Based on 9 Wall Street analysts offering 12 month price targets forDay One Biopharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Day One Biopharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

6.26 / 7.47Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Sentiment

By Acuity

154 / 348 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.